CSTL · Company research
Castle Biosciences, Inc. Common Stock (CSTL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,288 Shares of Stock - MarketBeat | Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,288 Shares of Stock MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| Castle Biosciences, Inc. (CSTL) Stock Price, News, Quote & History - Yahoo! Finance Canada | Castle Biosciences, Inc. (CSTL) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 13, 2026 | neutral | 0 | 0.6 |
| The chief commercial officer proposes selling 13,154 Castle Biosciences (CSTL) shares. - Stock Titan | The chief commercial officer proposes selling 13,154 Castle Biosciences (CSTL) shares. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Castle Biosciences Inc (CSTL) Shares Fall 4.8% -- What GF Score of 80 Tells Investors - GuruFocus | Castle Biosciences Inc (CSTL) Shares Fall 4.8% -- What GF Score of 80 Tells Investors GuruFocus | View source ↗ | GuruFocus | Oct 13, 2026 | neutral | 0 | 0.6 |
| In one case, a test flagged a 62% five-year risk of precancer or cancer. A later exam found missed changes. - Stock Titan | In one case, a test flagged a 62% five-year risk of precancer or cancer. A later exam found missed changes. Stock Titan | View source ↗ | Stock Titan | Oct 12, 2026 | neutral | 0 | 0.6 |
| Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Has Consensus Target Price of $42.00 According to Brokerages - MarketBeat | Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Has Consensus Target Price of $42.00 According to Brokerages MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| $CSTL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative | $CSTL stock is down 9% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 6, 2026 | neutral | 0 | 0.6 |
| Castle Biosciences (NASDAQ:CSTL) Stock Price Down 6.1% Following Insider Selling - MarketBeat | Castle Biosciences (NASDAQ:CSTL) Stock Price Down 6.1% Following Insider Selling MarketBeat | View source ↗ | MarketBeat | Oct 6, 2026 | neutral | 0 | 0.6 |
| An officer and two trusts propose selling 28,992 shares of Castle Biosciences (CSTL). - Stock Titan | An officer and two trusts propose selling 28,992 shares of Castle Biosciences (CSTL). Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Insider Selling: Castle Biosciences (NASDAQ:CSTL) COO Sells 4,153 Shares of Company Stock - MarketBeat | Insider Selling: Castle Biosciences (NASDAQ:CSTL) COO Sells 4,153 Shares of Company Stock MarketBeat | View source ↗ | MarketBeat | Oct 5, 2026 | neutral | 0 | 0.6 |
| Low-risk melanoma patients who skipped lymph node biopsy had 99.6% recurrence-free survival at five years. - Stock Titan | Low-risk melanoma patients who skipped lymph node biopsy had 99.6% recurrence-free survival at five years. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| A 55,000-square-foot lab is opening in Arizona for Castle Biosciences - Stock Titan | A 55,000-square-foot lab is opening in Arizona for Castle Biosciences Stock Titan | View source ↗ | Stock Titan | Sep 22, 2026 | neutral | 0 | 0.6 |
| Castle Biosciences (CSTL) Stock Climbs On Higher Sales Outlook Despite Margin Pressure - Simply Wall Street | Castle Biosciences (CSTL) Stock Climbs On Higher Sales Outlook Despite Margin Pressure Simply Wall Street | View source ↗ | Simply Wall Street | Aug 1, 2026 | neutral | 0 | 0.6 |
| Castle Biosciences (CSTL) Stock Rises on Q2 2026 Earnings - Quiver Quantitative | Castle Biosciences (CSTL) Stock Rises on Q2 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 30, 2026 | neutral | 0 | 0.6 |
| Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance | Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Jul 30, 2026 | neutral | 0 | 0.6 |
| CSTL Forecast — Price Target — Prediction for 2027 - TradingView | CSTL Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance | Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | May 6, 2026 | neutral | 0 | 0.6 |
| Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets - Yahoo Finance | Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets Yahoo Finance | View source ↗ | Yahoo Finance | Mar 20, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.